系统性肥大细胞增多症的肾脏及泌尿道受累
本文为叙述性综述,讨论系统性肥大细胞增多症(SM)患者肾脏及泌尿道受累的多种方式。SM可直接或间接累及肾脏,间接受累包括免疫介导的肾小球肾炎、单克隆沉积病和原发性轻链淀粉样变性;治疗晚期SM的新型抗肿瘤药物(非特异性酪氨酸激酶抑制剂)在一些患者中与肾功能障碍相关。
要点
- SM因KIT基因功能获得性突变导致肥大细胞在组织中过度积聚,肾脏直接受累罕见,但间接受累报道增多。
- SM可伴免疫介导的肾小球肾炎,如系膜增生性肾小球肾炎、膜性肾病和弥漫增生性肾小球肾炎。
- SM合并浆细胞异常时,可发生单克隆沉积病和原发性轻链淀粉样变性等肾脏损伤。
核心结论
- 本文综述了SM患者肾脏及泌尿道受累的多种方式,包括直接受累罕见、间接受累(免疫介导的肾小球肾炎、单克隆沉积病、原发性轻链淀粉样变性)以及治疗相关肾功能障碍。
研究设计与样本
- 叙述性综述,讨论SM患者肾脏及泌尿道受累的多种方式。
主要发现
- SM可直接累及肾脏罕见,但间接肾脏受累的报道日益增多。
- SM与免疫介导的肾小球肾炎相关,包括系膜增生性肾小球肾炎、膜性肾病和弥漫增生性肾小球肾炎。
- SM合并浆细胞异常时,可发生单克隆沉积病和原发性轻链淀粉样变性等肾脏损伤。
- 用于治疗晚期SM的非特异性酪氨酸激酶抑制剂在一些患者中与肾功能障碍相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Systemic mastocytosis (SM) is a disorder of excessive mast cell accumulation in tissues due to a somatic gain-of-function mutation, commonly in the KIT gene, which prevents apoptosis of mast cells. Whereas bone marrow, skin, lymph nodes, spleen and gastrointestinal tract are commonly involved, kidneys are rarely involved directly by SM. However, there are increasing reports of indirect kidney involvement in patients with SM. Novel anti-neoplastic agents to treat advanced forms of SM include non-specific tyrosine kinase inhibitors, which are reported to be associated with kidney dysfunction in some patients. SM is also associated with immune-mediated glomerulonephritis (GN) such as mesangioproliferative GN, membranous nephropathy and diffuse proliferative GN. Kidney injury, in the form of monoclonal deposition disease and primary light chain amyloidosis, is reported in SM associated with plasma cell dyscrasia. In this narrative review we discuss the various ways kidneys (and the urinary tract) are involved in patients with SM.
引用
- Bharati J, Shah N, Desai A, et al. Kidney and urinary tract involvement in systemic mastocytosis. Nephrol Dial Transplant. 2023. PMID: 37113073. doi:10.1093/ndt/gfad081
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。